ClinicalTrials.gg
Active, not recruitingNCT05513001Updated Mar 11, 2026

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

A Phase 3 interventional study of LOU064 (blinded) and Placebo in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 208 sites in 30 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
696
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.

Enrollment
Largest of 12
696 · median 347
Started
2022
with 1 other
Phase 3
9 of 12
1 open now
Registered
6th of 12
by date
Lead sponsor
12 of 12
Novartis Pharmaceuticals

Among the 12 studies testing remibrutinib in Chronic Urticaria, this one has the largest enrollment, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 6th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About remibrutinib

remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing remibrutinib in Chronic Urticaria, or all of them as a file.
02

Study summary

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies.

This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.

Read the detailed description

This is a Phase 3b multicenter, double-blind, placebo-controlled, randomized withdrawal, and open-label extension study to evaluate the efficacy and safety of remibrutinib 25 mg twice daily (b.i.d.) in adult CSU participants who have completed one of the preceding Phase 3 core studies. The study comprises 2 Epochs:

Epoch 1 is the initial study period and includes participants from preceding Phase 3 studies. It consists of a 24-week randomized withdrawal period where participants receive either remibrutinib 25 mg b.i.d. or placebo if their UAS7 score is less than 16. For those with a UAS7 score of 16 or higher, there is a 24-week open-label treatment period with remibrutinib 25 mg b.i.d. Participants are randomized 1:1 to the double-blind placebo-controlled withdrawal phase. All participants will continue their background H1-AH treatment. If participants relapse (UAS7 ≥ 16) in the blinded group, they enter the (Re-)treatment period of Epoch 1 and receive 24 weeks of open-label treatment with remibrutinib 25 mg b.i.d. After this period, they move to Epoch 2.

Epoch 2 is the second subsequent study period and consists of 24-week cycles that may include treatment-free observation and/or open-label (Re-)treatment periods with remibrutinib 25 mg b.i.d., with or without background H1-AH, at the investigator's discretion. Participants from future Phase 3 remibrutinib studies may also join Epoch 2 if approved. If participants relapse (UAS7 ≥ 16) during an observation period, they enter the next (Re-)treatment period for 24 weeks of treatment with remibrutinib 25 mg b.i.d. Participants completing an observation period with a UAS7 ≤ 6 will complete the study with an end-of-study (EOS) visit. Those with a UAS7 > 6 but \< 16 can enter the next (Re-)treatment period if continuous treatment is deemed necessary. Participants with a UAS7 \< 16 in the previous treatment period will receive remibrutinib monotherapy (without background H1-AH). If treatment continuation is not necessary, they complete the EOS visit and leave the study. Participants with a UAS7 ≥ 16 during the observation period will enter the corresponding (Re-)treatment period to continue treatment.

Throughout Epoch 2, the use of background H1-AH is at the investigator's discretion, except for participants with a UAS7 \< 16 in the previous treatment period, who will be treated with remibrutinib monotherapy.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • CSU
  • Brutons Tyrosine Kinase (BTK) inhibitor
  • Chronic Spontaneous Urticaria
  • Urticaria activity score
  • Hives severity score
  • Itch severity score
  • Extension
  • Randomized withdrawal
  • Retreatment upon relapse
  • Remibrutinib
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.
  • Male and female, adult participants ≥18 years of age.
  • Participants who successfully completed the preceding core studies CLOU064A2301, CLOU064A2302, CLOU064A1301, CLOU064A2304 or CLOU064A2305 according to the respective protocols.
  • Willing and able to adhere to the study protocol and visit schedule.

Exclusion criteria

Exclusion Criteria:

  • Significant bleeding risk or coagulation disorders.
  • History of gastrointestinal bleeding.
  • Requirement for anti- medication.
  • Requirement for anticoagulant medication.
  • History or current hepatic disease.
  • Evidence of cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
696 participants (actual)

Study arms

  • Experimental
    Arm 1: LOU064 (blinded)

    LOU064 (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)

    Drug: LOU064 (blinded) · Drug: LOU064 (open label)

  • Placebo comparator
    Arm 2: LOU064 Placebo (blinded)

    LOU064 placebo (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)

    Drug: Placebo · Drug: LOU064 (open label)

  • Experimental
    Arm 3: LOU064 (Open Label)

    LOU064 (open-label) taken orally for 24 weeks per treatment cycle (Arm 3)

    Drug: LOU064 (open label)

Interventions

  • LOU064 (blinded) active treatment

    Also known as: remibrutinib

  • DrugPlacebo

    Placebo

  • LOU064 (open-label) active treatment

    Also known as: remibrutinib

06

What researchers measure

Primary outcomes

  1. Time to first composite event (i.e., relapse (UAS7≥16)

    The efficacy of remibrutinib in CSU participants with a UAS7\<16 at Week 52 in the prior core study with respect to time to first of the three events: relapse or study treatment discontinuation due to lack of efficacy or intake of strongly confounding prohibited medication up to Week 24 compared to placebo. (Epoch 1) Time to first composite event (i.e., relapse (UAS7≥16), study treatment discontinuation due to lack of efficacy or intake of strongly confounding prohibited medication) during the randomized withdrawal period (Epoch 1) Urticaria Activity Score (UAS7) describes the number of hives with 0 being No Hives and 3 is most severe. The final score is calculated by adding together daily scores which can range from 0-6 for 7 days. The resulting maximum score is then 42.

    Time frame: 24 weeks

Secondary outcomes

  1. Number of participants with treatment-emergent (serious and non-serious) adverse events

    Occurrence of treatment-emergent (serious and non-serious) adverse events

    Time frame: 160 weeks

07

Study locations

208 sites
  • Allervie Clinical Research
    Birmingham, Alabama 35209, United States
  • Cahaba Derm and skin hlth ctr 27
    Birmingham, Alabama 35244, United States
  • Research Solutions of Arizona
    Litchfield Park, Arizona 85340, United States
  • Acuro Research Inc
    Little Rock, Arkansas 72205, United States
  • Arkansas Research Trials
    North Little Rock, Arkansas 72117, United States
  • Kern Research
    Bakersfield, California 93301, United States
  • Antelope Valley Clinical Trials
    Lancaster, California 93534, United States
  • Allergy and Asthma Consultants
    Redwood City, California 94063, United States
  • Asthma and Allergy Associates P C
    Colorado Springs, Colorado 80907, United States
  • Colorado Allergy and Asthma Ctr PC
    Denver, Colorado 80230, United States
  • UCONN Health Dermatology
    Farmington, Connecticut 06030-2840, United States
  • Florida Ctr Allergy Asthma Research
    Aventura, Florida 33180, United States
  • Finlay Medical Research
    Greenacres City, Florida 33467, United States
  • Miami Dade Medical Research
    Miami, Florida 33176, United States
  • Sarasota Clinical Research
    Sarasota, Florida 34233, United States
  • Allergy and Asthma Diagnostic Treatment Center
    Tallahassee, Florida 32308, United States
  • Aeroallergy Research Laboratories
    Savannah, Georgia 31406, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Endeavor Health
    Glenview, Illinois 60077, United States
  • Asthma and Allergy Center of Chicago S C
    River Forest, Illinois 60305, United States
  • Deaconess Clin Allerg Res Inst
    Evansville, Indiana 47715, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Allergy and Asthma Specialist P S C
    Owensboro, Kentucky 42301, United States
  • John Hopkins University
    Baltimore, Maryland 21204, United States
  • Institute for Asthma and Allergy PC
    Chevy Chase, Maryland 20815, United States
  • The Clinical Research Center
    St Louis, Missouri 63141, United States
  • Somnos Clinical Research
    Lincoln, Nebraska 68510, United States
  • Allergy Asthma Assoc Monmouth
    Little Silver, New Jersey 07739, United States
  • Oakview Dermatology
    Athens, Ohio 45701, United States
  • CR Services Acquisition US
    Columbus, Ohio 43213, United States
  • Optimed Research LLC
    Columbus, Ohio 43235, United States
  • Toledo Institute of Clinical Research
    Toledo, Ohio 43617, United States
  • Allergy Asthma and Clinical Research
    Oklahoma City, Oklahoma 73120, United States
  • Vital Prospects Clinical Research Institute
    Tulsa, Oklahoma 74136, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • National Allergy and Asthma Research LLS
    North Charleston, South Carolina 29420, United States
  • Orion Clinical Research
    Austin, Texas 78759, United States
  • Western Sky Medical Research
    El Paso, Texas 79924, United States
  • RFSA Dermatology
    San Antonio, Texas 78213, United States
  • Allergy Associates of Utah
    Sandy City, Utah 84093, United States
  • Bellingham Asthma Allergy and Immunology
    Bellingham, Washington 98225, United States
  • Seattle Allergy and Asthma Rsch
    Seattle, Washington 98115, United States
  • Allergy Asthma and amp Sinus Ctr S C
    Greenfield, Wisconsin 53228, United States
  • Novartis Investigative Site
    Berazategui, Buenos Aires B1837AVT, Argentina
  • Novartis Investigative Site
    CABA, Buenos Aires C1414AIF, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1902COS, Argentina
  • Novartis Investigative Site
    Buenos Aires, Nueve De Julio B6500BWQ, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province 2000, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000JKR, Argentina
  • Novartis Investigative Site
    Bahía Blanca, B8000JRB, Argentina
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    Capital Federal, C1023AAB, Argentina
  • Novartis Investigative Site
    Santa Fe, S3000FIL, Argentina
  • Novartis Investigative Site
    East Melbourne, Victoria 3002, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Santo André, São Paulo 09060-870, Brazil
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Sofia, 1407, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Calgary, Alberta T2M 1A6, Canada
  • Novartis Investigative Site
    Edmonton, Alberta T6G 1C3, Canada
  • Novartis Investigative Site
    Fredericton, New Brunswick E3B 1G9, Canada
  • Novartis Investigative Site
    Kingston, Ontario K7L 2V7, Canada
  • Novartis Investigative Site
    London, Ontario N6H 5L5, Canada
  • Novartis Investigative Site
    Niagara Falls, Ontario L2H 1H5, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1G 6C6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M3B 3S6, Canada
  • Novartis Investigative Site
    Verdun, Quebec H4G 3E7, Canada
  • Novartis Investigative Site
    Guangzhou, Guangdong 510091, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510630, China
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Wuxi, Jiangsu 214002, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310016, China
  • Novartis Investigative Site
    Beijing, 100050, China
  • Novartis Investigative Site
    Beijing, 100191, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Shanghai, 200443, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Medellín, Antioquia 050010, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlántico 080002, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlántico 080020, Colombia
  • Novartis Investigative Site
    Bogota, Cundinamarca 110221, Colombia
  • Novartis Investigative Site
    Brno, 602 00, Czechia
  • Novartis Investigative Site
    Olomouc, 779 00, Czechia
  • Novartis Investigative Site
    Plzen Bory, 301 00, Czechia
  • Novartis Investigative Site
    Prague, 150 06, Czechia
  • Novartis Investigative Site
    Hellerup, 2900, Denmark
  • Novartis Investigative Site
    Kobenhavn N V, 2400, Denmark
  • Novartis Investigative Site
    Angers, 49933, France
  • Novartis Investigative Site
    Antony, 92160, France
  • Novartis Investigative Site
    Bordeaux, 33075, France
  • Novartis Investigative Site
    Brest, 29609, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Paris, 75970, France
  • Novartis Investigative Site
    Pierre-Bénite, 69495, France

Showing the first 100 of 208 sites across 30 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Aug 2024, 20 months.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 20 months is below that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 23, 2022
StartActual
Dec 9, 2022
Primary completionActual
Aug 26, 2024
CompletionEst.
Aug 2, 2027
Results delay requested
Jul 29, 2025
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05513001
Responsible party
Sponsor
First posted
Aug 23, 2022
Start date
Dec 9, 2022
Primary completion
Aug 26, 2024
Completion
Aug 2, 2027 (estimated)
Last update
Mar 11, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion